Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1472545
This article is part of the Research Topic EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects View all 6 articles

Application of Disitamab vedotin in the Multiline Treatment of EGFR Mutation-Positive Lung Adenocarcinoma with Her-2 Overexpression

Provisionally accepted
Meiling Lan Meiling Lan 1*Tianyun Wang Tianyun Wang 1*Diexiao Luo Diexiao Luo 1*Yan Chen Yan Chen 2Wei Liang Wei Liang 1*Rui Kong Rui Kong 1*Qichao Xie Qichao Xie 1*
  • 1 The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 2 Daping Hospital, Army Medical University, Chongqing, China

The final, formatted version of the article will be published soon.

    Objective: To explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.We summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.The patient was diagnosed with lung adenocarcinoma 8 years ago. After first-line treatment, the lung lesions enlarged. Following second-line treatment 5 years ago, intracranial metastasis occurred. After third-line treatment 3 years ago, intracranial and lung lesions enlarged. New lesions in the lungs, liver, and spleen appeared after fourth-line treatment 32 months ago. Lung progression occurred after fifth-line treatment 29 months ago. Liver and lung progression occurred after sixth-line treatment 22 months ago. Lung progression occurred after seventh-line treatment 19 months ago. The patient underwent eighth-line treatment with disitamab vedotin (RC48) + lung radiotherapy + liver intervention 13 months ago. Currently, the patient's condition is stable, with a good quality of life, and the efficacy assessment is stable disease (SD). Conclusion: Her-2 overexpression can occur in late-stage EGFR-mutant lung adenocarcinoma after multiline treatment. RC48 can achieve sustained remission in these patients.

    Keywords: HER-2 overexpression, epidermal growth factor receptor, Lung Adenocarcinoma, Disitamab vedotin, efficacy, multiline treatment, conservative treatment

    Received: 22 Aug 2024; Accepted: 06 Nov 2024.

    Copyright: © 2024 Lan, Wang, Luo, Chen, Liang, Kong and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Meiling Lan, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Tianyun Wang, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Diexiao Luo, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Wei Liang, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Rui Kong, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Qichao Xie, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.